Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer’s disease: Where do we stand?

Volume: 57, Issue: 2, Pages: 99 - 113
Published: Oct 29, 2019
Abstract
Alzheimer’s disease (AD) is an incurable neurodegenerative disease characterized by progressive decline of cognitive abilities. Amyloid beta peptides (Aβ), Tau proteins and the phosphorylated form of the Tau protein, p-Tau, are the core pathological biomarkers of the disease, and their detection for the diagnosis of patients is progressively being implemented. However, to date, their quantification is mostly performed on cerebrospinal fluid...
Paper Details
Title
Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer’s disease: Where do we stand?
Published Date
Oct 29, 2019
Volume
57
Issue
2
Pages
99 - 113
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.